For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Tumor neo-vasculature, characterized by the development of abnormal, leaky and tortuous blood vessels, represents a key target for cancer imaging and therapy. Among the various recognized tools for measuring microvessel density is tomato (Lycopersicon esculentum) lectin, a single polypeptide glycoprotein that binds to sugar-containing proteins present on the endothelium.
TLectinSense™ 680 is a fluorescent in vivo endothelial cell imaging agent. TLectinSense 680 fluorescent agent is a near-infrared labeled macromolecule that targets the vasculature and enables imaging of blood vessels and angiogenesis. This agent in conjunction with PerkinElmer’s imaging instruments helps in assessing vascularity in vivo and in real time, without termination of mice, excision and processing of the tissue, thus improving the efficacy, early detection and monitoring of anti-angiogenic therapies.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||TLectinSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Angiogenesis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
The protein Tomato (L. esculentum) lectin is widely used for vascular,labeling, because the protein has high binding affinity for glycoprotein N-acetylglucosamines on the surface of vascular endothelial cells. The TLectinSense agent is a near-infrared fluorescent imaging probe designed and optimized for use in living animals. One of the gold standard,methods for vascular mapping ex vivo, is now enabled for use in vivo.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Tumor neo-vasculature, characterized by the development of abnormal, leaky and tortuous blood vessels, represents a key target for cancer imaging and therapy. Among the various recognized tools for measuring microvessel density is tomato (Lycopersicon esculentum) lectin, a single polypeptide glycoprotein that binds to sugar-containing proteins present on the endothelium. The aim of this study was to develop a near infra-red tomato lectin imaging agent to non-invasively assess tumor vasculature in vivo. Conjugation of the near infra-red fluorophore VivoTag 680XL (epsilon=210,000/M/cm; abs/em max 665/688 nm) to tomato lectin was carried out by addition of the fluorophore in a DMSO solution to lectin in aqueous sodium bicarbonate. Yields of greater than 95% were achieved, based on absorbance, with a typical loading of 2 dyes per lectin. The resulting agent, TLectinSenseTM 680 (TL680), preferentially labeled primary human umbilical vein endothelial cells. Specificity of the binding was validated by control experiments using free dye and competitive blockade with excess unlabeled tomato lectin. In vivo, non-invasive, real-time imaging and quantification of tumor neo-vasculature was performed in two models: matrigel plugs containing bFGF, VEGF and heparin injected into the flank of SKH-1 mice and nude mice bearing Lewis Lung Carcinoma tumors. Using Fluorescence Molecular Tomography (FMT®) 6 hours after TL680 (4 nmoles) intravenous injection, tumor endothelium-associated fluorescence was detected in matrigel plugs and this...
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.